Andrew Chadwick from PA Consulting Group - the leading international management, systems and technology consultancy - will warn pharmaceutical companies' R&D management about the perils of ill-considered technology investment, in his keynote presentation 'New Technologies: A poisoned chalice?' at SM
PA Consulting highlights the potential pitfalls of technology investment in drug discovery
I's conference, High Throughput Screening, at 15:20 on 24 January 2006 in London.
Andrew, a Consultant in PA's Life Sciences and Healthcare Practice, will provide insight on how to avoid four causes of waste and disappointment when seeking to improve drug discovery productivity: HTS investments that are ill-considered, ill-timed, ill-sited and ill-sized.
The paper will review some commonly stated goals of investment in new screening technology, and will consider alternative ways of achieving the same objectives, with reference to a 'value drivers' model of the value created by the drug discovery process, the costs incurred, and the true constraints on value creation.
It will illustrate the importance of timing investments right, and of striking the right balance between global sharing and local flexibility and immediacy of response. With reference to PA's experience in modelling discovery productivity, both at the detailed level of logistics and at the strategic level of pipeline quality and value creation/value for money, Andrew will show how some of the obvious rules for facility sizing, that neglect important areas of uncertainty, lead to waste (overcapacity) or to disappointment.
This paper will be of particular value to senior discovery managers, to screening group leaders and to technology assessment specialists involved in R&D facility investment appraisal, planning, enhancement and resource allocation decisions.
In presenting the paper, Andrew will draw from 25 years' experience in commercial R&D and informatics management, technology assessment, long-range planning, quantitative decision analysis, and modelling of benefits, risk and uncertainty on behalf of many of the World's leading pharmaceutical companies.
PA in Healthcare
PA supports clients' drug discovery, development, manufacturing and commercialisation activities from strategy to successful implementation. Our core consulting services focus around: strategies for commercial excellence; improving R&D effectiveness; and enhancing supply chain performance.
Our organisation is unique in that we invest heavily in our two technology centres in the US and UK. With over 200 scientists and engineers from the life sciences industry, we design, develop and deliver pharmaceutical products, drug-delivery devices, and novel scientific instruments.
PA's expertise addresses the most critical business issues that affect payers, providers and managed care companies. We advise on and support the implementation of new health policy, improving performance against targets, providing IT solutions to enable delivery of change, managing delivery of change, supporting organisational development, and modelling and analysing data to provide healthcare management information.
Our willingness to invest in IP has led to unique propositions in improved patient safety through product authentication at the point of dispensingT, addressing the growing concern over counterfeiting. We have also developed patented technologies to radically improve discovery planning and execution.
SMi's 4th annual Conference High Throughput Screening - the application of HTS in current and future drug discovery - 23 & 24 January 2006, Millennium Gloucester Hotel, London
PA Consulting Group is a leading management, systems and technology consulting firm. Operating worldwide in more than 35 countries, PA draws on the knowledge and experience of 3,000 people, whose skills extend from the initial generation of ideas, insights, solutions and new technology, all the way through to detailed implementation.
From the development of innovative strategies and solutions right through to their successful delivery, all of our work and support is based on deep sector insight and expertise. We work across the private and public sectors, with particular strengths in financial services, energy, life sciences and healthcare, government and public services, manufacturing, and telecommunications. We help our clients to design optimum strategies for growth, deliver effective IT that improves business performance, mobilise human resources, deliver complex programmes and major business transformations, and develop breakthrough products and processes through our unique applied technology capability.
As an employee-owned company, with no audit arm nor exclusive alliances with third-party vendors or service providers, we are answerable only to ourselves and our clients. This independence means the advice we give to clients, and the work we deliver, are based only on what is best for our clients' business. We will, however, work in non-exclusive alliances on specific programmes when it is in the best interests of our clients.
PA's independent, benefits-driven approach is founded on our strength in innovation, our responsiveness to our clients' needs, and our unyielding focus on delivery:
Innovation. Innovation comes in a variety of forms - in how customers' needs are identified and satisfied, in business models, in motivating and aligning staff, in the use of technology, and many more. PA has an unsurpassed track record in innovation, from developing pharmaceutical anti-counterfeiting measures and wireless technologies, to helping launch an innovative online bank, to development work that is helping alleviate poverty and boost the economies of developing countries.
Responsiveness. We recognise that each client and each problem have their own challenges and issues. Our solutions are therefore tailored to our clients' specific circumstances, drawing on the deep industry insight of our consultants. Our relationships with clients are characterised by respect, flexibility and collaboration, and we pride ourselves on the speed of our response and the dedication of our people.
Delivery. At PA, delivering client value is ingrained in our culture. We focus on detailed implementation, with a renowned track record of delivering innovative solutions that achieve lasting change. At PA, we see projects right through to the finishing line - and beyond - delivering significant and measurable value to our clients.
PA: Innovation. Responsiveness. Delivery.
For more information please contact:
Andrew Chadwick +44 (0)7887 540328 email: firstname.lastname@example.org
Beverley Adams +44 (0)1763 285260 email: email@example.com
or visit www.paconsulting.com/lifesciences
For an e-alert about PA's regular Impacts healthcare newsletter, click here:
PA Consulting Group is an innovation and transformation consultancy. We believe in the power of ingenuity to build a positive human future in a technology-driven world.